Schering-Plough Assumes Exclusive Worldwide Marketing Rights for Mometasone Furoate/Formoterol Combination for Asthma and COPD
KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced changes to its global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The changes will result in Schering-Plough assuming exclusive worldwide rights to develop and commercialize a fixed-dose combination of its inhaled corticosteroid ASMANEX(R) (mometasone furoate inhalation powder), and Novartis' long-acting beta2-adrenergic receptor agonist, FORADIL(R) (formoterol fumarate). Also as a result, Novartis will assume exclusive worldwide rights to develop and commercialize a fixed-dose combination of Schering-Plough's inhaled corticosteroid mometasone furoate with its investigational beta2-agonist QAB149 (indacaterol).
"Schering-Plough has a long history in developing therapies for treating respiratory diseases. This strategic action will allow us to focus our efforts within the asthma and COPD market," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "The investigational fixed-dose combination of ASMANEX and FORADIL, both of which are currently approved and marketed as individual products, is in Phase III development for the treatment of asthma and COPD. Schering-Plough anticipates filing the mometasone furoate/formoterol combination for the treatment of asthma with the Food and Drug Administration in the first half of 2009," added Koestler.
This is the latest development in a successful long-term relationship between Novartis and Schering-Plough which dates back to 2002. The collaboration was
|SOURCE Schering-Plough Corporation|
Copyright©2009 PR Newswire.
All rights reserved